View More View Less
  • 1 Bajcsy-Zsilinszky Kórház, Budapest, Maglódi út 89–91., 1106

Absztrakt

A Clostridium difficile az egyik leggyakoribb fertőzés a daganatos betegek között. Diagnózisát nehezíti, hogy a fertőzés tünetei és az onkológiai kezelések mellékhatásai hasonlóak lehetnek. Maga a kemoterápia is elősegítheti a Clostridium difficile-infekció kialakulását. Bár számos kockázati faktor ismert, ezek hiányában is kialakulhat a fertőzés. A fatális Clostridium difficile-infekció kockázati faktora a neutropenia, ami egyben a kemoterápia mellékhatása is. Ezért, ha daganatos betegek esetén a potenciális infekció tünetei megjelennek (például diarrhoea naponta több mint háromszor, 38,5 °C-ot meghaladó láz, colitis, szérumkreatinin-szint gyors emelkedése) a Clostridium difficile-fertőzést ki kell zárni. Amennyiben a fertőzés igazolódik, azt a leghatékonyabb módon kezelni kell. Orv. Hetil., 2016, 157(28), 1110–1116.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Kelly, C. P., Pothoulakis, C., LaMont, J. T.: Clostridium difficile colitis. N. Engl. J. Med., 1994, 330(4), 257–262.

  • 2

    Cowardin, C. A., Petri, W. A. Jr.: Host recognition of Clostridium difficile and the innate immune response. Anaerobe, 2014, 30, 205–209.

  • 3

    Voth, D. E., Ballard, J. D.: Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev., 2005, 18(2), 247–263.

  • 4

    Kelly, C P., LaMont, J. T.: Clostridium difficile – more difficult than ever. N. Engl. J. Med., 2008, 359(18), 1932–1940.

  • 5

    Lavergne, V., Beauséjour, Y., Pichette, G., et al.: Lymphopenia as a novel marker of Clostridium difficile infection recurrence. J. Infect., 2013, 66(2), 129–135.

  • 6

    Cohen, S. H., Gerding, D. N., Johnson, S., et al.: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol., 2010, 31(5), 431–455.

  • 7

    Baarc, M.C., Depitre, C., Corthier, G., et al.: Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo. Antimicrob Agents Chemother 1992, 36(6), 1332–1335.

  • 8

    Chopra, T., Chandrasekar, P., Salimnia, H., et al.: Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantation. Clin. Transplant., 2011, 25(1), E82–E87.

  • 9

    Starr, J. M., Impallomeni, M.: Risk of diarrhoea, Clostridium difficile and cefotaxime in the elderly. Biomed Pharmacother 1997, 51(2), 63–67.

  • 10

    Polage, C. R., Gyorke, C. E., Kennedy, M. A., et al.: Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern. Med., 2015, 175(11), 1792–1801.

  • 11

    Kaier, K., Frank, U.: Relationship between antibiotic consumption and Clostridium difficile-associated diarrhea: an epidemiological note. Antimicrob. Agents Chemother., 2009, 53(10), 4574–4575.

  • 12

    Biagi, E., Nylund, L., Candela, M., et al.: Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE, 2010, 5(5), e10667.

  • 13

    McDonald, L. C., Owings, M., Jernigan, D. B.: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg. Infect. Dis., 2006, 12(3), 409–415.

  • 14

    Al-Tureihi, F. I., Hassoun, A., Wolf-Klein, G., et al.: Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J. Am. Med. Dir. Assoc., 2005, 6(2), 105–108.

  • 15

    Fainstein, V., Bodey, G. P, Fekety, R.: Relapsing pseudomembranous colitis associated with cancer chemotherapy. J. Infect. Dis., 1981, 143(6), 865.

  • 16

    Yeom, C. H., Cho, M. M., Baek, S. K., et al.: Risk factors for the development of Clostridium difficile-associated colitis after colorectal cancer surgery. J. Korean Soc. Coloproctol., 2010, 26(5), 329–333.

  • 17

    Gérard, M., Defresne, N., Van der Auwera, P., et al.: Polymicrobial septicemia with Clostridium difficile in acute diverticulitis. Eur. J. Microbiol. Infect. Dis., 1989, 8(4), 300–302.

  • 18

    Hebert, C., Du, H., Peterson, L. R., et al: Electronic health record-based detection of risk factors for Clostridium difficile infection relapse. Infect. Control Hosp. Epidemiol., 2013, 34(4), 407–414.

  • 19

    Kim, J. W., Lee, K. L., Jeong, J. B., et al.: Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J. Gastroenterol., 2010, 16(28), 3573–3577.

  • 20

    O’Keefe, S. J.: Tube feeding, the microbiota, and Clostridium difficile infection. World J. Gastroenterol., 2010, 16(2), 139–142.

  • 21

    Louie, T. J., Cannon, K., Byrne, B., et al.: Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin re-expression and recurrence of CDI. Clin. Infect. Dis., 2012, 55(Suppl. 2), S132–S142.

  • 22

    Sergio, S., Pirali, G., White, R., et al.: Lipiarmycin, a new antibiotic from Actinoplanes III. Mechanism of action. J. Antibiot. (Tokyo), 1975, 28(7), 543–549.

  • 23

    Cornely, O. A., Miller, M. A., Fantin, B., et al.: Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J. Clin. Oncol., 2013, 31(19), 2493–2499.

  • 24

    Mullane, K.: Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther. Adv. Chronic Dis., 2014, 5(2), 69–84.

  • 25

    Mullane, K. M., Miller, M. A., Weiss, K., et al.: Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin. Infect. Dis., 2011, 53(5), 440–447.

  • 26

    Mullane, K. G., Crook, D., Cornely, O. A., et al.: Renal impairment and response to fidaxomicin versus vancomycin in patients with Clostridium difficile infection. Proc. 49th Annual Meeting Infectious Diseases Society of America, October 20–23, 2011, Boston, MA.

  • 27

    Cornely, O. A., Fantin, B., Mullane, K., et al.: Clostridium difficile-associated diarrhea in cancer patients treated with fidaxomicin or vancomycin. Annual Meeting of the American Society of Clinical Oncology, June 1–5, 2012, Chicago, IL.

  • 28

    Louie, T. J., Miller, M. A., Crook, D. W., et al.: Effect of age on treatment outcomes in Clostridium difficile infection. J. Am. Geriatr. Soc., 2013, 61(2), 222–230.

  • 29

    Pépin, J., Routhier, S., Gagnon, S., et al.: Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin. Infect. Dis., 2006, 42(6), 758–764.

  • 30

    Bakken, J. S.: Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe, 2009, 15(6), 285–289.

  • 31

    Benson, A. B. 3rd, Ajani, J. A., Catalano, R. B., et al.: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol., 2004, 22(14), 2918–2926.

  • 32

    Gorschlüter, M., Hahn, C., Ziske, C., et al.: Low frequency of enteric infections by Salmonella, Shigella, Yersinia and Campylobacter in patients with acute leukemia. Infection, 2002, 30(1), 22–25.

  • 33

    McDonald, L. C., Killgore, G. E., Thompson, A., et al.: An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med., 2005, 353(23), 2433–2441.

  • 34

    Muldoon, E. G., Epstein, R., Logvinenko, T., et al.: The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients. Anaerobe, 2013, 24, 79–81.

  • 35

    Cudmore, M. A., Silva, J. Jr., Fekety, R., et al.: Clostridium difficile colitis associated with cancer chemotherapy. Arch. Intern. Med., 1982, 142(2), 333–335.

  • 36

    Bishop, K. D., Castillo, J. J.: Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk. Lymphoma, 2012, 53(8), 1617–1619.

  • 37

    Redelings, M. D., Sorvillo, F., Mascola, L.: Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerg. Infect. Dis., 2007, 13(9), 1417–1419.

  • 38

    Stringer, A. M., Gibson, R. J., Bowen, J. M., et al.: Chemotherapy-induced modifications to gastrointestinal microflora: Evidence and implications of change. Curr. Drug Metab., 2009, 10(1), 79–83.

  • 39

    Morales Chamorro, R., Serrano Blanch, R., Mendez Vidal, M. J., et al.: Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. Clin. Transl. Oncol., 2005, 7(6), 258–261.

  • 40

    Resnik, E., Lefevre, C. A.: Fulminant Clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy. Int. J. Gynecol. Cancer, 1999, 9(6), 512–514.

  • 41

    Emoto, M., Kawarabayashi, T., Hachisuga, M. D., et al.: Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol. Oncol., 1996, 61(3), 369–372.

  • 42

    Toi, Y., Sugawara, S., Kobayashi, T., et al.: Prospective study of chemotherapy-induced Clostridium difficile infection in lung cancer patients. J. Clin. Oncol., 2012, 30(15 Suppl.), e19521.

  • 43

    Anand, A, Glatt, A. E.: Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin. Infect. Dis., 1993, 17(1), 109–113.

  • 44

    El-Mahallawy, H. A., El-Din, N. H., Attia, I. A., et al.: Clostridium difficile associated diarrhea in pediatric oncology patients receiving chemotherapy. J. Egypt. Nat. Cancer Inst., 2001, 13(4), 285–290.

  • 45

    Ansari, J., Choo, B., Fernando, I.: Fatal Clostridium difficile infection associated with vinorelbine chemotherapy: case report and literature review. J. Infect. Chemother., 2010, 16(3), 210–212.

  • 46

    Nonomura, Y., Otsuka, A., Endo, Y., et al.: Clostridium difficile colitis and neutropenic fever associated with docetaxel chemotherapy in a patient with advanced extramammary Paget’s disease. Case Rep. Dermatol., 2012, 4(2), 177–180.

  • 47

    Khan, A., Raza, S., Batul, S. A., et al.: The evolution of Clostridium difficile infection in cancer patients: epidemiology, pathophysiology, and guidelines for prevention and management. Recent Pat. Antiinfect. Drug Discov., 2012, 7(2), 157–170.

  • 48

    Fang, W. J., Jing, D. Z., Luo, Y., et al.: Clostridium difficile carriage in hospitalized cancer patients: a prospective investigation in eastern China. BMC Infect. Dis., 2014, 14, 523.

  • 49

    Hwang, K. E., Hwang, Y. R., Seol, C. H., et al.: Clostridium difficile infection in lung cancer patients. Jpn J. Infect. Dis., 2013, 66(5), 379–382.

  • 50

    Gorschlüter, M., Glasmacher, A., Hahn, C., et al.: Clostridium difficile infection in patients with neutropenia. Clin. Infect. Dis., 2001, 33(6), 786–791.

  • 51

    Zacharioudakis, I. M., Ziakas, P. D., Mylonakis, E.: Clostridium difficile infection in the Hematopoietic Unit: A meta-analysis of published studies. Biol. Blood Marrow Transplant., 2014, 20(10), 1650–1654.

  • 52

    Caimi, P. F.: Clostridium difficile infection is a frequent but well-controlled event after hematopoietic cell transplantation. Rev. Bras. Hematol. Hemoter., 2015, 37(6), 371–372.

  • 53

    Stewart, D. B., Yacoub, E., Zhu, J.: Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients. J. Gastrointest. Surg., 2012, 16(8), 1566–1572.

  • 54

    Heard, S. R., Wren, B., Barnett, M. J., et al.: Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains. Epidemiol. Infect., 1988, 100(1), 63–72.

  • 55

    Bartlett, J. G.: Historical perspectives on studies of Clostridium difficile and difficile infection. Clin. Infect. Dis., 2008, 46(Suppl. 1), S4– S11.

  • 56

    Loo, V. G., Bourgault, A. M., Poirier, L., et al.: Host and pathogen factors for Clostridium difficile infection and colonization. N. Engl. J. Med., 2011, 365(18), 1693–1703.

  • 57

    Keller, J. M., Surawicz, C. M.: Clostridium difficile infection in the elderly. Clin. Geriatr. Med., 2014, 30(1), 79–93.

  • 58

    Stevens, V., Dumyati, G., Fine, L. S., et al.: Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin. Infect. Dis., 2011, 53(1), 42–48.

  • 59

    Hensgens, M. P., Goorhuis, A., Dekkers, O. M., et al.: Time interval of increased risk for Clostridium difficile infections after exposure to antibiotics. J. Antimicrob. Chemother., 2012, 67(3), 742–748.

  • 60

    Kelly, C. P.: Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin. Microbiol. Infect., 2012, 18(Suppl. 6), 21–27.

  • 61

    D’Agostino, R. B. Sr., Collins, S. H., Pencina, K. M., et al.: Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin. Infect. Dis., 2014, 58(10), 1386–1393.

  • 62

    Louie, T. J., Miller, M. A., Mullane, K. M., et al.: Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med., 2011, 364(5), 422–431.

  • 63

    Esmaily-Fard, A., Tverdek, F. P., Crowther, D. M., et al.: The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer. Pharmacotherapy, 2014, 34(11), 1220–1225.

  • 64

    Yoon, Y. K., Kim, M. J., Sohn, J. W., et al.: Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy. Support. Care Cancer, 2014, 22(8), 2039–2048.

  • 65

    Rodríguez Garzotto, A., Mérida García, A., Muñoz Unceta, N., et al.: Risk factors associated with Clostridium difficile infection in adult oncology patients. Support. Care Cancer, 2015, 23(6), 1569–1577.

  • 66

    Krishna, S. G., Zhao, W., Apewokin, S. K., et al.: Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients. Transplant Infect. Dis., 2013, 15(5), 493–501.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 0 11 6
Dec 2020 0 15 17
Jan 2021 0 12 21
Feb 2021 0 11 21
Mar 2021 0 5 8
Apr 2021 0 7 10
May 2021 0 0 0